Cel Sci CVM
NYSE CVM
$2.08 +0.02 (+0.73%)
As of: Oct 1, 2026 · 3:59 PM EDT

Cel Sci (CVM) Price to Sales (2017)

Updated

Cel Sci's Price to Sales was 80.40 in fiscal Q3 2017 (quarter ended Jun 30, 2017).

Analysis

Cel Sci (CVM) Price to Sales (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Cel Sci 3.69 Mn -21.96 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 80.40
API Access

Cel Sci Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=CVM&period=max&api_key=YOUR_API_KEY